Abstract
Pharmacogenomics is the study of inherited variation in drug disposition and response which focuses on associated genetic polymorphisms. This is an emerging field with great potential to lead to individualized medicine, optimizing therapeutic outcomes, and avoidance of unnecessary drug toxicity. Many barriers remain in this field limiting its clinical applicability. Current cardiovascular related medications with pharmacogenomic labeling are limited but include clopidogrel, warfarin, and drugs from the β-blocker and statin classes of medications. There is lack of pediatric focused research in this area which is necessary given developmental differences that additionally affect drug metabolism and response.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Hines R, McCarver G. Pharmacogenomics and the future of drug therapy. Pediatr Clin North Am. 2006;53:591–619.
Johnson J, Cavallari L, Beitelshees A, Lewis J, Shuldiner A, Roden D. Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther. 2011;90:519–31.
Johnson JA, Cavallari LH. Cardiovascular pharmacogenomics. In: Raizada MK, Paton JFR, Kasparov S, Katovich MJ, editors. Contemporary cardiology: cardiovascular genomics. Totowa: Humana Press Inc; 2005. p. 71–93.
Leeder J, Kearns G. The challenges of delivering pharmacogenomics into clinical pediatrics. Pharmacogenomics J. 2002;2:141–3.
Roden D, Johnson J, Kimmel S, et al. Cardiovascular pharmacogenomics. Circ Res. 2011;109:807–20.
Shin J, Kayser S, Langaee T. Pharmacogenomics: from discovery to patient care. Am J Health Syst Pharm. 2009;66:625–37.
US Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labels. Available at: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/. Accessed 26 Mar 2012.
Visscher H, Amstutz U, Sistonen J, Ross C, Hayden M, Carleton BC. Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics. J Cardiovasc Pharmacol. 2011;58:228–39.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Sawyer, J.E., Chamberlain, A.R., Cooper, D.S. (2014). Pharmacogenomics. In: Munoz, R., da Cruz, E., Vetterly, C., Cooper, D., Berry, D. (eds) Handbook of Pediatric Cardiovascular Drugs. Springer, London. https://doi.org/10.1007/978-1-4471-2464-1_3
Download citation
DOI: https://doi.org/10.1007/978-1-4471-2464-1_3
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-2463-4
Online ISBN: 978-1-4471-2464-1
eBook Packages: MedicineMedicine (R0)